FindTrial
Sign In

A real-world clinical study investigating the clinical efficacy, safety, and comprehensive landscape of immune responses comparing neoadjuvant immunotherapy with neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell

A real-world clinical study investigating the clinical efficacy, safety, and comprehensive landscape of immune responses comparing neoadjuvant immunotherapy with neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074951
Enrollment
Unknown
Registered
2023-08-21
Start date
2020-09-01
Completion date
Unknown
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophagus cancer

Interventions

Case series: None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-80 years, both genders; 2) Confirmed esophageal squamous cell carcinoma; 3) According to the eighth edition of TNM staging, the clinical stage is locally advanced (T2-4N0-2M0) (potentially resectable or marginally resectable), which is not suitable for endoscopic exfoliation or resection, and has no distant metastasis; 4) Neoadjuvant PD-1/PD-L1 immunotherapy (e.g., pembrolizumab, sintilimab) with chemotherapy (paclitaxel/albumin-bound paclitaxel plus carboplatin/cisplatin) or chemoradiotherapy; 5) Underwent curative surgery.

Exclusion criteria

Exclusion criteria: 1) Esophageal adenocarcinoma or mixed adenocarcinoma with small cell component; 2) Concurrent other tumors; 3) No further surgery.

Design outcomes

Primary

MeasureTime frame
Disease free survival;—

Secondary

MeasureTime frame
Overall survival;Pathological complete response rate;objective remission rate;—

Countries

China

Contacts

Public ContactDing Zhenyu

West China Hospital, Sichuan University

dingzhenyu@scu.edu.cn+86 189 8060 1957

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026